Call: +7 771 977 66 65, +7 705 421 2277
Sign in or Register
My basket

Astana Biomed Group, an authorized Abcam distributor in Central Asia

Abiomed homepage

  • Categories
    Signal Transduction
    Cancer
    Epigenetics and Nuclear Signaling
    Immunology
    Cell Biology
    Cardiovascular
    Neuroscience
    Tags & Cell Markers
    Kits/ Lysates/ Other
    Developmental Biology
    Microbiology
    Biochemicals
    Secondary antibodies
    Isotype/Loading Controls
    Antibody Arrays
  • About us
  • Partners
  • Contact
    Address

    Saryarka 32, 18, 010000, Astana city, Kazakhstan

    Telephone +7 771 977 66 65, +7 705 421 2277

    Email

    laboratory@ctlab.kz, orders@abiomed.kz

Back to category
Epigenetics and Nuclear Signaling Transcription Other factors

Human IRF1 knockout HeLa cell pellet (ab278831)

Price and availability

670 ₸

Availability

Order now and get it on Tuesday March 09, 2021

Human IRF1 knockout HeLa cell pellet (ab278831)
  • ChIP - Anti-Histone H3 antibody - Nuclear Loading Control and ChIP Grade (ab1791)
  • ChIP - Anti-Histone H3 antibody - Nuclear Loading Control and ChIP Grade (ab1791)
  • ChIP - Anti-Histone H3 antibody - Nuclear Loading Control and ChIP Grade (ab1791)

You may also be interested in

Product image
Anti-Nkx3.1 antibody [NKX3.1/2576] - BSA and Azide free (ab257325)
Product image
Anti-HNF1 alpha antibody [EPR23054-108] (ab272693)
Product image
Anti-ATF3 antibody (ab176872)
Product image
Anti-DLX3 antibody [EPR8762(2)] (ab178428)

Overview

  • Product name

    Human IRF1 knockout HeLa cell pellet
    See all IRF1 kits
  • Product overview

    Abcam’s knockout cell pellets give you access to native proteins, without the need to culture cells. Our knockout cell pellets are prepared from our single-gene knockout cell lines and provide an additional offering to our cell lysates.

    Cells are snap-frozen to provide high quality pellets that are suitable for extraction with alternative lysis buffers or for preparation of lysates from subcellular fractions. Our knockout cell pellets are suitable for a variety of applications, including PCR, gene expression profiling and DNA library preparation.

  • Parental Cell Line

    HeLa
  • Organism

    Human
  • Mutation description

    Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 2 and 2 bp deletion in exon 2 and Insertion of the selection cassette in exon 2.
  • Passage number

  • Knockout validation

    Sanger Sequencing
  • Notes

    Pellet size: 5 million cells/vial.

    This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

Properties

  • Storage instructions

    Store at -80°C. Please refer to protocols.
  • Components 1 kit
    Human IRF1 knockout HeLa cell pellet 1 vial
    Human wild-type HeLa cell pellet 1 vial
  • Research areas

    • Epigenetics and Nuclear Signaling
    • Transcription
    • Other factors
    • Cardiovascular
    • Atherosclerosis
    • Apoptosis
  • Cell type

    epithelial
  • Disease

    Adenocarcinoma
  • Gender

    Female
  • STR Analysis

    Amelogenin X D5S818: 11, 12 D13S317: 12, 13.3 D7S820: 8, 12 D16S539: 9, 10 vWA: 16, 18 TH01: 7 TPOX: 8, 12 CSF1PO: 9, 10

Target

  • Function

    Specifically binds to the upstream regulatory region of type I IFN and IFN-inducible MHC class I genes (the interferon consensus sequence (ICS)) and activates those genes. Acts as a tumor suppressor.
  • Involvement in disease

    Defects in IRF1 are a cause of gastric cancer (GASC) [MIM:613659]; also called gastric cancer intestinal or stomach cancer. Gastric cancer is a malignant disease which starts in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. The term gastric cancer or gastric carcinoma refers to adenocarcinoma of the stomach that accounts for most of all gastric malignant tumors. Two main histologic types are recognized, diffuse type and intestinal type carcinomas. Diffuse tumors are poorly differentiated infiltrating lesions, resulting in thickening of the stomach. In contrast, intestinal tumors are usually exophytic, often ulcerating, and associated with intestinal metaplasia of the stomach, most often observed in sporadic disease.
  • Sequence similarities

    Belongs to the IRF family.
    Contains 1 IRF tryptophan pentad repeat DNA-binding domain.
  • Post-translational
    modifications

    Sumoylation represses the transcriptional activity and displays enhanced resistance to protein degradation. Inactivates the tumor suppressor activity. Elevated levels in tumor cells. Major site is Lys-275. Sumoylation is enhanced by PIAS3 (By similarity). Desumoylated by SENP1 in tumor cells and appears to compete with ubiquitination on C-terminal sites.
    Ubiquitinated. Appears to compete with sumoylation on C-terminal sites.
  • Cellular localization

    Nucleus.
  • Target information above from: UniProt accession P10914 The UniProt Consortium
    The Universal Protein Resource (UniProt) in 2010
    Nucleic Acids Res. 38:D142-D148 (2010) .

    Information by UniProt
  • Alternative names

    • Interferon regulatory factor 1
    • Interferon regulatory factor 1 isoform +I9
    • Interferon regulatory factor 1 isoform d78
    • Interferon regulatory factor 1 isoform delta4
    • Interferon regulatory factor 1 isoform delta7
    • IRF 1
    • IRF-1
    • IRF1
    • IRF1_HUMAN
    • MAR
    • MAR1
    see all

Properties

  • Storage instructions

    Store at -80°C. Please refer to protocols.
  • Components 1 kit
    Human IRF1 knockout HeLa cell pellet 1 vial
    Human wild-type HeLa cell pellet 1 vial
  • Research areas

    • Epigenetics and Nuclear Signaling
    • Transcription
    • Other factors
    • Cardiovascular
    • Atherosclerosis
    • Apoptosis
  • Cell type

    epithelial
  • Disease

    Adenocarcinoma
  • Gender

    Female
  • STR Analysis

    Amelogenin X D5S818: 11, 12 D13S317: 12, 13.3 D7S820: 8, 12 D16S539: 9, 10 vWA: 16, 18 TH01: 7 TPOX: 8, 12 CSF1PO: 9, 10

Images

  • Sanger Sequencing - Human IRF1 knockout HeLa cell pellet (ab278831)
    Sanger Sequencing - Human IRF1 knockout HeLa cell pellet (ab278831)

    Allele-1: 2 bp deletion in exon 2

     

  • Sanger Sequencing - Human IRF1 knockout HeLa cell pellet (ab278831)
    Sanger Sequencing - Human IRF1 knockout HeLa cell pellet (ab278831)

    Allele-2: 1 bp deletion in exon 2

     

  • Sanger Sequencing - Human IRF1 knockout HeLa cell pellet (ab278831)
    Sanger Sequencing - Human IRF1 knockout HeLa cell pellet (ab278831)

    Allele-3: Insertion of the selection cassette in exon 2

     

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Clear all

Recently viewed products

  •  
  • Product image

    Anti-hapten 4-hydroxy-3-nitrophenyl acetyl (NP) antibody [B1-8] (ab206536)

  •  
  • Product image

    Anti-LRRK2 antibody [MJFF5 (68-7)] - BSA and Azide free (ab237040)

  •  
  • Product image

    Anti-Isoleucyl tRNA synthetase antibody [EPR10267] - BSA and Azide free (ab249075)

  •  
  • Product image

    HRP Anti-Cdc37 (phospho S13) antibody [EPR4879] (ab202364)

  •  
  • Product image

    Recombinant human Insulin Receptor protein (ab80251)

  •  
  • Product image

    Recombinant human GCN5L2 protein (Active) (ab268694)

Get resources and offers direct to your inbox Sign up
© 2021 Astana Biomed Group LLP. All rights reserved.